Janssen
Janssen says cabotegravir/rilpivirine combo matches three-drug HIV maintenance therapy
February 24, 2016Research and Development Janssen, ViiV
Janssen has announced 32-week data from an ongoing phase IIb study of an HIV regimen comprised of its rilpivirine and …
Johnson & Johnson hit by fall in 2015 sales
January 27, 2016Research and Development, Sales and Marketing Janssen, Johnson and Johnson, financial results, revenue, sales
Full year sales at the healthcare giant Johnson & Johnson fell by 6% in 2015, to just over $70 billion, …
Patients sue J&J for $800m for ‘hiding antibiotic side effects’
January 22, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, Janssen, Johnson and Johnson, Levaquin, Margaret Hamburg, lawsuit, levofloxacin
Six users of Johnson & Johnson’s antibiotic Levaquin are to sue the company for up to $870 million, claiming the …
ViiV and Janssen to test new HIV regimen in Phase III trial
January 7, 2016Manufacturing and Production, Medical Communications, Research and Development Edurant, HIV, Janssen, ViiV Healthcare, cabotegravir, collaboration, phase III, rilpivirine
Janssen has formalised its collaboration with ViiV Healthcare on the Phase III development and commercialisation of a two-drug regimen to …
Janssen, Enterome and Kymab in research collaborations
January 7, 2016Research and Development Crohn's, Crohn’s disease, Enterome, Janssen, MD Anderson, alliance, antibodies, collaboration, crohn's disease, immuno-oncology, kymab, research
Several pharma companies have announced new collaborations, to research potential new drugs for Crohn’s disease, and immuno-oncology treatments for cancer. …
Janssen and Bavarian Nordic to collaborate on HPV vaccine
December 23, 2015Research and Development Bavarian Nordic, HPV, Janssen, Vaccine, human papillomavirus, prime boost
Janssen has announced a new collaboration and license agreement with Bavarian Nordic to develop a vaccine for chronic Human Papillomavirus …
NICE publishes draft guidance on two prostate cancer treatments
December 11, 2015Medical Communications, Research and Development, Sales and Marketing Astellas, Janssen, NICE, Xtandi, Zytiga, prostate cancer
NICE has issued final draft guidance recommending Astellas Pharma’s Xtandi (enzalutamide) in prostate cancer prior to chemotherapy, but not Janssen’s …
Janssen submits Stelara for EU approval for Crohn’s
December 9, 2015Sales and Marketing Crohn’s disease, EMA, European Medicines Agency, Janssen, Stelara, crohn's disease, ustekinumab
Janssen today announced that it has submitted an application to the European Medicines Agency, seeking approval of Stelara in Crohn’s …
Strong cancer trial data for Janssen at ASH 2015
December 8, 2015Research and Development Cancer, Janssen, darzalex, imbruvica, oncology
Janssen presented new cancer trial data at the 57th Annual American Society of Haematology (ASH) meeting Orlando, Florida – with …
Janssen in new collaboration to take on TB
December 3, 2015Research and Development FIND, Janssen, antibiotic resistance, tuberculosis
Janssen has announced a new collaboration with the non-profit organisation FIND to step-up the fight against the public health threat …
J&J announces new partnerships in fight against HIV/AIDS
December 1, 2015Research and Development AIDS, HIV, Janssen
Johnson &Johnson is entering four new public-private partnerships aimed at significantly reducing the burden of HIV incidence among young girls …
GSK begins Phase III study of sirukumab in giant cell arteritis
November 26, 2015Business Services, Research and Development, Sales and Marketing GSK, Janssen
GSK today announced it has begun a Phase III study evaluating sirukumab, a human anti-interleukin (IL)-6 monoclonal antibody, for the …
Janssen buys licence to diabetes and obesity drugs from Hanmi
November 10, 2015Manufacturing and Production, Research and Development Janssen, diabetes, hanmi
Janssen could spend up to a billion dollars to buy for novel clinical stage biologics to treat diabetes and obesity. …
Encouraging late-stage results for Stelara in Crohn’s disease
October 21, 2015Research and Development, Sales and Marketing Crohn’s disease, Janssen, Stelera, crohn's disease, ustekinumab
Janssen is planning new regulatory submissions for Stelera after Phase III data found it improved responses and remission rates in …
Janssen submits EMA application for myeloma drug
September 14, 2015Sales and Marketing Janssen, daratumumab, multiple myeloma
Janssen has submitted a new marketing authorisation application for European approval of daratumumab for the treatment of patients with relapsed …
Latest content
Medtronic secures CE Mark for new cardiac pacing portfolio
Dermatology leader Doncker is new Onicor CEO
